You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行报告》美银美林升中生制药(01177.HK)目标价至10.6元评级「买入」
阿思达克 08-05 14:45

美银美林发表报告指,对於市场关注在「4+7」药品集中采购措施下,中生制药(01177.HK)旗下药品恩替卡韦(Entecavir)及氟比洛芬(flurbiprofen)收益大受影响,而其他药物销售能否作出弥补?该行有系统地推算中生制药於仿制药的业务表现,当中包括2018至2019年以及2019至2021年分别有20及40种仿制药获批,料将会为2019至2021年分别产生19亿、41亿及61亿元人民币销售额。

该行补充,预期「4+7」延伸计划将会於2020年实施,而第二轮「4+7」则於2021年启动。整体而言,该行估计,该公司於2019年至2021年及以後销售会有强劲增长,重申「买入」评级,目标价则由9.5元调升至10.6元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account